To examine the in vivo significance of the improved anti-inflammatory and immunosuppressive functions of SHC-MSCs, we injected these cells into a humanized GVHD mouse model transplanted with human PBMNCs [8] and compared the therapeutic outcomes with those achieved using naïve and PLK1-overexpressing MSCs (Fig. 4a,b). This evidence concerns the gene PLK1 and graft versus host disease.